Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls

Alvotech reported Q2 2026 revenue of $106M versus the $111.5M forecast (-$5.5M, -4.9%) and an adjusted EPS loss of -$0.054 versus -$0.0368 expected (46.7% worse). Results were pressured by Reykjavik manufacturing slowdowns tied to facility/quality-system upgrades, though the company said output returned to planned levels by end-Q2 and reaffirmed full-year guidance of $650M–$700M revenue and $180M–$220M adjusted EBITDA, targeting a strongest Q4. Despite the earnings/revenue misses, the stock was flat at ~$3.99 after hours, suggesting limited reaction as management pointed to improving production and later regulatory catalysts.

Analysis

ALVO’s setup is less about the reported miss and more about timing mismatch between shipments and true demand. If manufacturing is back to plan, the next 1-2 quarters should show operating leverage because the company is rebuilding inventory into a portfolio that is now broad enough to matter; that favors a sharper rebound in product revenue than the market is likely modeling. The second-order winner is the broader biosimilar channel: once a supplier clears a manufacturing overhang, pharmacy/payer customers tend to reload quickly, which can create a catch-up quarter before normalization.

The main losers are the originator franchises tied to AVT05/06 and the other late-stage programs, especially where first-wave biosimilar entry can force tender resets and accelerate price compression. JNJ is the obvious economic counterparty in Simponi/Simponi Aria, but the larger competitive implication is that ALVO’s pipeline breadth raises the odds of overlapping erosion across multiple biologics at once. That said, the market will care more about execution than molecule count; if ALVO can’t convert approvals into reliable supply, the competitive advantage stays theoretical.

Risk is highly asymmetric around Q4 2026 to early 2027. A clean approval sequence plus no further Reykjavik disruption could re-rate the stock, but the balance-sheet remains the constraint: elevated debt and cash interest mean equity value depends on free-cash-flow inflection, not just EBITDA. Contrarianly, consensus may be underestimating how much of the weakness is a one-time supply issue; but it may also be overestimating how quickly replenishment turns into durable run-rate growth, because partner ordering can front-load one quarter and leave a hole the next. The thesis is falsified if Q3 fails to show sequential product-revenue improvement or if any new manufacturing/regulatory slip pushes the Q4 cadence to the right.

Key Decisions for Investors

• Watchlist long ALVO into Q3 print only if sequential product revenue turns up and gross margin begins to normalize; otherwise stay sidelined. Risk/reward improves materially only when the market can see the inventory-rebuild cycle, not just management guidance.
• Consider a tactical long ALVO / short JNJ relative-value pair into the Q4 FDA window. The upside is biosimilar launch optionality and share capture; the risk is that litigation or approval timing slips and JNJ remains a low-beta counterweight.
• If implied volatility is still cheap, use call spreads in ALVO targeting the Q4 2026 approval window rather than outright stock. That caps downside if manufacturing or litigation timing disappoints while preserving convexity if approvals land on schedule.
• Avoid chasing the post-earnings shrug higher until there is evidence of sustained supply recovery. If Q3 stays flat sequentially, the stock likely reverts to being a financing-and-execution story rather than a launch story.